Abstract:
PURPOSE: A method for evaluating the efficiency of a sun screen is provided to accurately evaluate efficiency of blocking blue/violet light. CONSTITUTION: A method for evaluating the efficiency of a sun screen comprises: a step of applying a subject on a sunlight permeable material; a step of irradiating skin cells with the sunlight; and a step of collecting the skin cells and measuring gene expression level in the cells. The sunlight is UV ray with 290-400 nm of wavelength or blue/violet light with 400-500 nm of wavelength. The sunlight permeable material is a quartz plate or band pass filter. The skin cells include keratinocytes, fibroblast, or melanocytes.
Abstract:
PURPOSE: A composition for promoting the differentiation of human mesenchymal stem cells to adipocytes, containing Sterculiae scaphigerae semen extract, is provided to enhance the volume and elasticity of skin. CONSTITUTION: An external use skin composition for promoting the differentiation of adipocytes contains 0.0001-30 wt% of Sterculiae scaphigerae semen extract as an active ingredient. The mesenchymal stem cell is derived from humans. A pharmaceutical composition for promoting the differentiation into adipocytes contains Sterculiae scaphigerae semen extract as an active ingredient. The dose of the extract is 0.001mg/kg/day-2000mg/kg/day.
Abstract translation:目的:提供一种用于促进人类间充质干细胞分化为脂肪细胞的组合物,其含有Sterculiae scaphigerae精液提取物,以增强皮肤的体积和弹性。 构成:用于促进脂肪细胞分化的外用皮肤组合物含有0.0001-30重量%的白e精液提取物作为活性成分。 间充质干细胞来源于人类。 用于促进分化成脂肪细胞的药物组合物含有仙人掌精液提取物作为活性成分。 提取物的剂量为0.001mg / kg /天-2000mg / kg /天。
Abstract:
본 발명은 자기회합성을 갖는 양친성 고분자를 사용하여 난용성 육모 물질을 포집시켜 제조한 나노입자 및 이를 함유하는 두피 넓게는 피부 외용제 조성물에 관한 것이다. 보다 구체적으로, 본 발명은 소수성 폴리에스테르 고분자(A)와 친수성 고분자(B)를 결합시켜 제조한 블록공중합체(AB) 형태의 자기회합성(self-assembling)을 갖는 양친성 고분자를 사용하여 수용액상에서 난용성의 발모 활성 성분인 사이클로스포린을 포집시켜 제조한 나노입자 및 이를 유효성분으로 함유하는 두피 및 피부 외용제 조성물에 관한 것이다. 본 발명에 의한 나노입자는 난용성 또는 불용성의 생리활성 유효성분인 사이클로스포린을 포집시켜 나노 수준의 크기로 캡슐화하여 수분산 상태의 입자로 제조한 것으로, 활성 성분의 모낭 전달 효과 및 흡수율이 뛰어나고, 다양한 외용제 제형에 용이하게 적용할 수 있는 뛰어난 효과가 있다.
Abstract:
PURPOSE: A composition containing octyl salicylate or phenylbenaimidazole sulfonic acid is provided to effectively block UVC and UVB. CONSTITUTION: A composition for blocking UVC contains one or more selected from the group consisting of octyl salicylate or phenylbenzimidazole sulfonic acid as an active ingredient. The composition is used in the form of solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, foundation, oil-in-water, or water-in-oil. The maximum absorbance is in the wavelength of 200-290 nm.
Abstract:
PURPOSE: A composition containing Potentilla chinensis extract for tightening pore or suppressing sebum secretion is provided to suppress SNARE(soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex formulation. CONSTITUTION: A composition for tightening pore or suppressing sebum contains Potentilla chinensis extract as an active ingredient. The composition suppresses membrane fusion between synaptic vesicle and presynaptic membrane. The Potentilla chinensis extract isolated using water, ethanol, or anhydrous methanol. A pharmaceutical composition or a cosmetic composition contains the composition. The cosmetic composition is manufactured in the form of astringent, lotion, massage cream, essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, or body essence.
Abstract:
PURPOSE: A composition containing polyphenol compounds for pore tightening is provided to suppress complex formation of SNARE(soluble Nethylmaleimide-sensitive factor attachment protein receptor). CONSTITUTION: A composition for pore tightening contains 0.0001-30 weight% of polyphenol compounds as active ingredients. The polyphenol compounds are myricetin, quercetin, luteolin, delphinidin, cyaniding, butein, ellagic acid, EGCG(Epigallocatechin gallate), fisetin, derivative thereof. An external use skin composition contains the composition for pore tightening. The external use skin composition is a percutenous formulation. A pharmaceutical composition or cosmetic composition contains the composition for pore tightening.
Abstract:
본 발명은 하기 화학식 1로 표시되는 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로 함유하는 SPC 수용체 활성으로 유발되는 염증관련 질환에 유용한 그의 용도에 관한 것이다. 본 발명의 2,4,5-삼중치환-1,3-티아졸 유도체는 사람으로부터 유래된 진피세포 및 마우스를 이용한 동물실험을 통하여 항염증 효과를 검색한 결과, SPC 수용체에 대한 우수한 억제활성을 규명함으로써, 상기 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용 가능한 그의 염을 유효성분으로 함유하여 SPC 수용체 활성으로 유발되는 아토피성 피부염, 기타 질환에서 나타나는 염증, 소양증 또는 피부 감염증에 유효한 염증관련 질환 치료제로서 유용하게 활용될 수 있다.
(상기 식에서, R 1 , R 2 , 및 R 3 는 명세서에서 정의한 바와 같다.) 1,3-티아졸, 스핀고실포스포릴콜린, 아토피 피부염, 염증치료제
Abstract:
A composition for regulating melanogenesis, which contains RhoGDI-alpha is provided to efficiently promote or inhibit melanogenesis using siRNA gene which suppresses RhoGDI-alpha expression. A composition for regulating melanogenesis comprises a RhoGDI-alpha protein or gene coding the same or a complementary gene of RhoGDI-alpha gene. The composition for regulating melanogenesis inhibits the expressions of MITF and tyrosinase. The composition for regulating melanogenesis promotes the expression of MITF and tyrosinase. A screening method of the composition for regulating melanogenesis includes confirmation of regulation of RhoGDI-alpha expression, activation or function.
Abstract:
A pharmaceutical composition comprising sphingosylphosphorylcholine or derivatives thereof is provided to inhibit proliferation and promote differentiation of keratinocyte, inhibit proliferation of splenocyte and T cell, induce reduction of leucocyte, and reduce mouse ear swelling induced by TPA(tetradecanoyl phorbol acetate), so that the composition is useful for treating psoriasis. A pharmaceutical composition for treating psoriasis comprises sphingosylphosphorylcholine(SPC) represented by the formula(1) or derivatives thereof and is formulated as tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, sterile injection or sterile powder, wherein the daily dosage is 1-100 mg/kg, preferably 5-70 mg/kg.